Journal of the American Academy of Dermatology
Volume 62, Issue 2 , Pages 291-299 , February 2010

Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation

  • Kavita Menon, MD

      Affiliations

    • Department of Dermatology, New York University, New York, New York
    • ,
  • Abby S. Van Voorhees, MD

      Affiliations

    • Department of Dermatology, University of Pennsylvania, Philadelphia, Pennsylvania
    • ,
  • Bruce F. Bebo Jr., PhD

      Affiliations

    • National Psoriasis Foundation, Portland, Oregon
    • ,
  • Dafna D. Gladman, MD

      Affiliations

    • University of Toronto School of Medicine, Toronto, Ontario, Canada
    • ,
  • Sylvia Hsu, MD

      Affiliations

    • Department of Dermatology, Baylor College of Medicine, Houston, Texas
    • ,
  • Robert E. Kalb, MD

      Affiliations

    • Department of Dermatology, State University of New York School of Medicine and Biomedical Sciences, Buffalo, New York
    • ,
  • Mark G. Lebwohl, MD

      Affiliations

    • Department of Dermatology, Mount Sinai School of Medicine, New York University, New York, New York
    • ,
  • Bruce E. Strober, MD, PhD

      Affiliations

    • Department of Dermatology, New York University, New York, New York
    • Corresponding Author InformationReprint requests: Bruce E. Strober, MD, PhD, Ronald O. Perelman Department of Dermatology, New York University, 560 First Ave, TCH-158, New York, NY 10016-6497.
    • ,
  • National Psoriasis Foundation

,Accepted 30 March 2009.

References 

  1. Mallon E, Bunker CB. HIV-associated psoriasis. AIDS Patient Care & Stds. 2000;14:239–246
  2. Montazeri A, Kanitakis J, Bazex J. Psoriasis and HIV infection. Int J Dermatol. 1996;35:475–479
  3. Bartlett BL, Khambaty M, Mendoza N, Tremaine AM, Gewirtzman A, Tyring SK. Dermatological management of human immunodeficiency virus. Skin Therapy Lett. 2007;12:1–3
  4. Shekelle PG, Woolf SH, Eccles M, Grimshaw J. Clinical guidelines: developing guidelines. BMJ. 1999;318:593–596
  5. Gray JD, Bottomley W, Layton AM, Cotterill JA, Monteiro E. The use of calcipotriol in HIV-related psoriasis. Clin Exp Dermatol. 1992;17:342–343
  6. Houpt KR, Beer JZ, Horn TD, Moy JA, Zmudzka BZ, Cruz PD. Ultraviolet therapy of HIV-infected individuals: a panel discussion. Semin Cutan Med Surg. 1997;16:241–245
  7. Zmudzka BZ, Beer JZ. Ultraviolet therapy and patients with HIV infection. Arch Dermatol. 1998;134:1025–1026
  8. Fotiades J, Lim HW, Jiang SB, Soter NA, Sanchez M, Moy J. Efficacy of ultraviolet B phototherapy for psoriasis in patients infected with human immunodeficiency virus. Photodermatol Photoimmunol Photomed. 1995;11:107–111
  9. Fotiades J, Soter NA, Sanchez MR, Moy JA. A three-year follow-up evaluation on 28 HIV-positive patients treated with ultraviolet B (UVB) phototherapy. Chicago, IL: Poster presented at: Annual Meeting of the Society for Investigative Dermatology; 1995;104:P660
  10. Meola T, Soter NA, Ostreicher R, Sanchez M, Moy JA. The safety of UVB phototherapy in patients with HIV infection. J Am Acad Dermatol. 1993;29:216–220
  11. Ranki A, Puska P, Mattinen S, Lagerstedt A, Krohn K. Effect of PUVA on immunologic and virologic findings in HIV-infected patients. J Am Acad Dermatol. 1991;24:404–410
  12. Horn TD, Morison WL, Farzadegan H, Zmudzka BZ, Beer JZ. Effects of psoralen plus UVA radiation (PUVA) on HIV-1 in human beings: a pilot study. J Am Acad Dermatol. 1994;31:735–740
  13. Pechère M, Yerly S, Lemonnier E, Krischer J, Perrin L, Saurat JH. Impact of PUVA therapy on HIV viremia: a pilot study. Dermatology. 1997;195:84–85
  14. Duvic M, Crane MM, Conant M, Mahoney SE, Reveille JD, Lehrman SN. Ziduvudine improves psoriasis in human immunodeficiency virus-positive males. Arch Dermatol. 1994;130:447–451
  15. Fischer T, Schwörer H, Vente C, Reich K, Ramadori G. Clinical improvement of HIV-associated psoriasis parallels reduction of HIV viral load induced by effective antiretroviral therapy. AIDS. 1999;13:628–629
  16. Vittorio Luigi De Socio G, Simonetti S, Stagni G. Clinical improvement of psoriasis in an AIDS patient effectively treated with combination antiretroviral therapy. Scand J Infect Dis. 2006;38:74–75
  17. Mamkin I, Mamkin A, Ramanan SV. HIV-associated psoriasis. The Lancet Infectious Diseases. 2007;7:496
  18. Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin therapy is effective for psoriasis associated with human immunodeficiency virus infection. Arch Dermatol. 1997;133:711–715
  19. Allen BR. Use of cyclosporin for psoriasis in HIV-positive patient. Lancet. 1992;339:686
  20. Tourne L, Durez P, Van Vooren JP, Farber CM, Liesnard C, Heenen M, et al. Alleviation of HIV-associated psoriasis and psoriatic arthritis with cyclosporine. J Am Acad Dermatol. 1997;37:501–502
  21. Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol. 1994;31:372–375
  22. Masson C, Chennebault JM, Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis?. J Rheumatol. 1995;22:2191
  23. Duvic M, Johnson TM, Rapini RP, Freese T, Brewton G, Rios A. Acquired immunodeficiency syndrome-associated psoriasis and Reiter's syndrome. Arch Dermatol. 1987;123:1622–1632
  24. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumor necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis. 2008;67:710–712
  25. Sellam J, Bouvard B, Masson C, Rousière M, Villoutreix C, Lacombe K, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine. 2007;74:197–200
  26. Bartke U, Venten I, Kreuter A, Gubbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol. 2004;150:784–786
  27. Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol. 2007;34:1353–1355
  28. Aboulafia DM, Bundow A, Wiske K, Ochs UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc. 2000;75:1093–1098
  29. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol. 2008;144:453–456
  30. Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol. 2006;45:689–692
  31. Sharma VK, Dutta B, Ramam M. Hydroxyurea as an alternative therapy for psoriasis. Indian J Dermatol Venereol Leprol. 2004;70:13–17
  32. Kumar B, Saraswat A, Kaur I. Rediscovering hydroxyurea: its role in recalcitrant psoriasis. Int J Dermatol. 2001;40:530–534
  33. Breuer-McHam J, Simpson E, Dougherty I, Bonkobara M, Ariizumi K, Lewis DE. Activation of HIV in human skin by ultraviolet B radiation and its inhibition by NFkappaB blocking agents. Photochem Photobiol. 2001;74:805–810
  34. Gelfand JM, Rudikoff D, Lebwohl M, Klotman ME. Effect of UV-B phototherapy on plasma HIV type 1 RNA viral level: a self-controlled prospective study. Arch Dermatol. 1998;134:940–945
  35. Stern RS, Mills DK, Krell K, Zmudzka BZ, Beer JZ. HIV-positive patients differ from HIV-negative patients in indications for and type of UV therapy used. J Am Acad Dermatol. 1998;39:48–55
  36. Morrison WL. PUVA therapy is preferable to UVB phototherapy in the management of HIV-associated dermatoses. Photochem Photobiol. 1996;64:267–268
  37. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008. pp. 1-139. Available from: URL: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed March 21, 2009.
  38. Townsend BL, Cohen PR, Duvic M. Zidovudine for the treatment of HIV-negative patients with psoriasis: a pilot study. J Am Acad Dermatol. 1995;32:994–999
  39. Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumor necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B and HIV infection. Ann Rheum Dis. 2006;65:983–989
  40. Van Zander J, Orlow SJ. Efficacy and safety of oral retinoids in psoriasis. Expert Opin Drug Saf. 2005;4:129–138
  41. Lisziewicz J, Foli A, Wainberg M, Lori F. Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns. Drug Saf. 2003;26:605–624
  42. Sanne I, Smego RA, Mendelow BV. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?. Int J Infect Dis. 2001;5:43–48
  43. Lori F, Lisziewicz J. Rationale for the use of hydroxyurea as an anti-human immunodeficiency virus drug. Clin Infect Dis. 2000;30:S193–S197
  44. Gibbs MA, Sorensen SJ. Hydroxyurea in the treatment of HIV-1. Ann Pharmacother. 2000;34:89–93

 Funding sources: None.

 Disclosure: Dr Van Voorhees has been a consultant, investigator, or speaker for Abbott, Amgen, Astellas, Centocor, Genentech, Incyte, Connetics, Warner Chilcott, Photomedix, Roche, and Synta. She has a significant conflict of interest with Merck. Dr Bebo is employed by the National Psoriasis Foundation. The Foundation receives unrestricted financial support from Abbott, Centocor, Amgen, Wyeth, Genentech, Astellas, Stiefel, Galderma, Warner Chilcott, and Photomedix. Dr Gladman has been a consultant, investigator, or advisory board member for Abbott, Amgen, Wyeth, Centocor, and Schering. Dr Hsu has been a consultant for Abbott, Amgen, Biogen Idec, Centocor, and Genentech. She has been a clinical investigator for Amgen and Centocor. Dr Kalb has been an investigator and consultant for Abbott, Amgen, Centocor, Astellas, Warner-Chilcott, Stiefel, and Genentech. Dr Lebwohl has been a consultant for Abbott, Amgen, Astellas, Centocor, Genentech, UCB Pharma, Stiefel, Triax, Pharmaderm, Medicis, Novartis, and Warner Chilcott. He has been a speaker for Abbott, Amgen, Astellas, Centocor, and Genentech. Dr Strober has been a speaker, advisor, consultant, and/or investigator for Abbott, Amgen, Astellas, Genentech, Centocor, and Wyeth. Dr Menon has no conflicts of interest to declare.

PII: S0190-9622(09)00393-4

doi: 10.1016/j.jaad.2009.03.047

Journal of the American Academy of Dermatology
Volume 62, Issue 2 , Pages 291-299 , February 2010

Article Tools

* Image Usage & Resolution